For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $8.16 in the last session, up 2.77% from day before closing price of $7.94. In other words, the price has increased by $2.77 from its previous closing price. On the day, 0.89 million shares were traded. DNA stock price reached its highest trading level at $8.32 during the session, while it also had its lowest trading level at $7.75.
Ratios:
We take a closer look at DNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.71 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.54.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 25 ’24 when Che Austin bought 99 shares for $7.99 per share.
Che Austin bought 99 shares of DNA for $916 on Oct 24 ’24. On Oct 23 ’24, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $9.27 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 502957088 and an Enterprise Value of 145960352. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.33 while its Price-to-Book (P/B) ratio in mrq is 0.48. Its current Enterprise Value per Revenue stands at 0.792 whereas that against EBITDA is -0.23.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $75.20, while it has fallen to a 52-week low of $5.26. The 50-Day Moving Average of the stock is 6.96%, while the 200-Day Moving Average is calculated to be -69.79%.
Shares Statistics:
According to the various share statistics, DNA traded on average about 1.44M shares per day over the past 3-months and 944830 shares per day over the past 10 days. A total of 38.13M shares are outstanding, with a floating share count of 35.44M. Insiders hold about 32.60% of the company’s shares, while institutions hold 43.88% stake in the company. Shares short for DNA as of 1728950400 were 7879004 with a Short Ratio of 5.47, compared to 1726185600 on 6345269. Therefore, it implies a Short% of Shares Outstanding of 7879004 and a Short% of Float of 25.259999999999998.
